One shot or two? study tests best way to give tdap and RSV vaccines in pregnancy

NCT ID NCT07097012

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at whether it's safe and effective to give the Tdap vaccine (for whooping cough) and the RSV vaccine at the same doctor's visit during pregnancy, or if they should be given separately. The researchers will recruit 60 healthy pregnant individuals and randomly assign them to receive both vaccines together or at different visits. The main goal is to see if a larger trial is possible, but they will also track side effects and immune responses in mothers and babies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tdap vaccine (tetanus, diphtheria, acellular pertussis) and RSV vaccine (respiratory syncytial virus)

What this could lead to

If successful, this could show that giving both vaccines at the same visit is safe and effective, simplifying prenatal care and protecting both mother and baby from whooping cough and RSV.

What could go wrong

This is a small pilot study with only 60 participants, focused on feasibility, not on proving the vaccines work. Results may not apply to all pregnant individuals, and the study may not detect rare side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diphtheria pertussis prevention target respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Canadian Center for Vaccinology

    RECRUITING

    Halifax, Nova Scotia, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Centre hospitalier universitaire Ste-Justine

    RECRUITING

    Montreal, Quebec, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Ottawa Hospital Research Institute

    RECRUITING

    Ottawa, Ontario, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Vaccine Evaluation Center

    ACTIVE_NOT_RECRUITING

    Vancouver, British Columbia, Canada